Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Encofosbuvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Encofosbuvir is an oral antiviral tablet for chronic hepatitis C. It was developed and is made in China by YiChang HEC ChangJiang Pharmaceutical, where it is sold as 东英贺® (Chinese name 艾考磷布韦片). It is never taken alone: it is always paired with a second new Chinese antiviral, netanasvir phosphate capsules, and the two together make a 12-week, all-oral course.
China's National Medical Products Administration (NMPA) approved it in March 2025, for adults with:
It is a prescription liver medicine and should be used under a hepatologist or gastroenterologist.
To multiply, the hepatitis C virus needs an enzyme called NS5B polymerase. Encofosbuvir is a nucleotide "prodrug": once inside liver cells it is converted into its active form, which blocks that enzyme. Netanasvir works on a different viral protein, NS5A. Blocking the virus at two points at the same time is what allows the course to clear it.
Approval was based on a phase 2/3 study in China (NCT05395416), run by the makers, in adults with genotype 1, 2, 3 or 6 infection. According to the company's 2025 and 2026 reimbursement filings, 95% of patients were cured overall, meaning no virus could be found 12 weeks after the last dose (SVR12). By genotype the cure rates were 99% (genotype 1), 99% (genotype 2), 78% (genotype 3) and 92% (genotype 6), and 92.3% in people with compensated cirrhosis. China's drug review centre noted an SVR12 of 94.1% in the double-blind part of the phase 3 study. The full results have not yet been published in an international journal.
If a dose is missed, it should be taken as soon as possible on the same day; if the day has passed, simply take the next dose at the usual time and never double up. Older patients and people with mild kidney problems do not need a different dose.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Never used alone: it only works as part of the two-drug combination with netanasvir, so the warnings for netanasvir also apply.
Side effects: in the pooled phase 2 and 3 safety data (442 patients on the combination), side effects were reported in 41.0% of patients, against 31.3% on placebo, and most were mild or moderate. The most common was raised uric acid in the blood. Raised cholesterol and triglycerides were also seen in at least 5% of patients. The company reports no serious side effects linked to the study medicines. Safety in pregnancy and breastfeeding is not covered in the published summary, so discuss this with your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and we found no approval by the US FDA or the European Medicines Agency.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it is always taken with netanasvir, we import both medicines together for the full course. For another China-approved hepatitis C option, see our page on Alfosbuvir.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 28 tablets of 0.3 g (4 strips of 7), which is two weeks of treatment at two tablets a day, so a full 12-week course needs 6 boxes, plus 3 boxes of netanasvir. The tablets travel in their sealed original packs and are stored as directed on the pack, under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid specialist's prescription.
Hepatitis C clinics in Delhi can start the paperwork quickly, and our New Delhi dispatch point keeps transit time short for the whole course.
Gastroenterologists in Mumbai can request both medicines of the pair in one order, so the patient starts with everything in hand.
Patients in Bangalore can have the tablets and capsules delivered home or to the clinic once the genotype report and prescription are checked.
Liver specialists in Chennai can share the viral load and genotype reports with us to begin a named-patient import.
We plan the 12-week supply in advance for Hyderabad patients, so there is no break in the daily doses.
For Kolkata and the north-east, we time the delivery to match the start date the hepatologist has set.
Patients in Pune receive the same documented import route, with updates at each step.
Doctors in Ahmedabad can coordinate the import for patients with genotype 1, 2, 3 or 6 infection who need this combination.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating liver clinic.
Patients across Rajasthan can receive the full course without travelling, as long as the import is in their own name.
We coordinate delivery for patients treated at public and private gastroenterology centres across Uttar Pradesh.
Patients in Kerala can have both medicines delivered together to their home or clinic in Kochi and nearby towns.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
